Supplementary Data

Table S1: Complete sample metadata and accession information for *Mtb* HN878-infected B6 and *Parp9^{-/-}* mouse RNA sequencing study. (RNAseq data were deposited at the Sequence Read Archive (SRA) on the NCBI website <u>https://www.ncbi.nlm.nih.gov/sra</u> under BioProject accession number PRJNA753056.)

Table S2: Read counts, relative gene expression levels, gene annotations, and differential expression data (four comparisons) for every mouse gene available by RNA sequencing from B6 and *Parp9^{-/-}* mice (RNAseq data were deposited at the Sequence Read Archive (SRA) on the NCBI website <u>https://www.ncbi.nlm.nih.gov/sra</u> under BioProject accession number PRJNA753056.)

Supplementary Figure1.

			Human				
C	CFU:exp corre			cant different	Significant spline on		
Gene	corre	ation			days to TB plot		
	Direction	P value	Controller / Naive	Progressor / Naive	Progressor / Controller	Direction	P value
PARP1	Up	0.0033	Up	Up	-	-	-
PARP2	Down	0.013	-	-	-	-	-
PARP3	-	-	-	-	Up	-	-
PARP4	Up	0.018	Up	Up	-	-	-
PARP5	-	-	Up	Up	-	Down	0.044
PARP6	Down	1.2E-07	-	-	Down	-	-
PARP7	-	-	-	Up	-	-	-
PARP8	Up	<10 ⁻¹⁰	Up	Up	Up	-	-
PARP9	Up	<10 ⁻¹⁰	Up	Up	Up	Up	0.0011
PARP10	Up	1.1E-08	Up	Up	Up	Up	0.015
PARP11	Up	<10 ⁻¹⁰	Up	Up	Up	-	-
PARP12	Up	<10 ⁻¹⁰	Up	Up	Up	-	-
PARP13	Up	<10 ⁻¹⁰	Up	Up	Up	-	-
PARP14	Up	<10 ⁻¹⁰	Up	Up	Up	Up	0.0014
PARP15	(No mouse	e ortholog)	(No	mouse orth	-	-	
PARP16	Down	2.8E-08	Down	Down	-	Down	0.0027

Supplementary Figure 1: Bacterial CFU: expression correlation pattern for the PARP isoforms

Genetically diverse outbred (DO) or *Parp9*^{-/-} mice were infected with *Mtb* HN878 (100 CFU) by the aerosol route. RNA isolated from mouse lung homogenates, collected at 30 dpi, was subjected to bulk RNA sequencing. The Pearson correlations and associated *P* values (based on the number of samples) between the detected bacterial load in the lungs (CFU) and the gene expression level of PARP genes are shown in the first column. Significant differential expression patterns with human TB are also shown for all the differentially expressed PARP isoforms (based on Ahmed et al. 2020(1)), as well as significant associations with TB progression in humans (based on Scriba et al. 2017(2)). "Up" refers to upregulation of PARP genes in association with TB.

Supplementary Figure 2.



Supplementary Figure 2: Expression of parylating ADP ribosylated PARP isoforms in DO mice progressors

Genetically diverse outbred (DO) mice were infected with *Mtb* HN878 (100 CFU) by the aerosol route. RNA was isolated from mouse lung homogenates, collected at 30 dpi, and subjected to bulk RNA sequencing. Expression of poly ADP ribosylated PARP isoforms obtained from controllers and progressor *Mtb*-infected DO mice. (A) Upregulated isoforms and (B) downregulated isoforms. All *P*-values shown on the expression swarm plots represent FDR-corrected significance values for differential expression calculated by DESeq2 (naïve n = 10, controller n = 12 and progressor n = 16). ***** *P* < 10⁻⁵, **** *P* < 10⁻⁴, **P<10⁻². Data is derived from datasets from Ahmed et al. 2020 (1).

Supplementary Figure 3.



Supplementary Figure 3: Expression of mono ADP ribosylated PARP isoforms in DO mice

Genetically diverse outbred (DO) were infected with *Mtb* HN878 (100 CFU) by the aerosol route. RNA isolated from mouse lung homogenates, collected at 30 dpi was subjected to bulk RNA sequencing. Expression of upregulated (A) and downregulated (B) mono ADP ribosylated PARP isoforms across the lung transcriptional profiles obtained from controllers and progressor *Mtb*-infected DO mice. All *P*-values shown on the expression swarm plots represent FDR-corrected significance values for differential expression calculated by DESeq2 (naïve n = 10, controller n = 12 and progressor n = 16). ***** *P* < 10^{-5} , *** *P* < 10^{-3} , **P<10⁻². Data is derived from datasets from Ahmed et al. 2020(1).



Supplementary Figure 4:

Supplementary Figure 4: IFN- γ and IL-1 β production is decreased in *Mtb*-infected

Parp9^{-/-} mice

B6 or *Parp9^{-/-}* mice were infected with *Mtb* HN878 (100 CFU) by the aerosol route. (A) IFN-γ and (B) IL-1β were measured in lung homogenates on 30, 60, 100 and 120 dpi by ELISA. The data points represent the mean \pm SEM, n = 5 per group. Significance was determined by unpaired two-tailed students t-test. *P*≤0.05 is considered significant.

Supplementary Figure 5



C Significant reactome pathway enrichment among the 1,104 genes significantly higher during *Mtb* HN878 infection in *Parp9*-/-but not B6 mice

Reactome		Total	#	FDR-
pathway	Description	pathway	Significant	
patrivay		size	genes	value
R-MMU-1430728	Metabolism	1810	212	0
R-MMU-71291	Metabolism of amino acids and derivatives	250	48	3.5E-08
R-MMU-140877	Formation of Fibrin Clot (Clotting Cascade)	39	17	8.7E-08
R-MMU-140837	Intrinsic Pathway of Fibrin Clot Formation	23	12	2.6E-06
R-MMU-174824	Plasma lipoprotein assembly, remodeling, and clearance	62	19	5.0E-06
R-MMU-8852276	The role of GTSE1 in G2/M progression after G2 checkpoint	70	20	6.6E-06
R-MMU-166658	Complement cascade	48	16	1.3E-05
R-MMU-382556	ABC-family proteins mediated transport	97	23	2.1E-05
R-MMU-211859	Biological oxidations	251	41	2.5E-05
R-MMU-156588	Glucuronidation	24	11	2.5E-05
R-MMU-8963899	Plasma lipoprotein remodeling	25	11	3.8E-05
R-MMU-5358346	Hedgehog ligand biogenesis	60	17	4.1E-05
R-MMU-977606	Regulation of Complement cascade	42	14	4.1E-05
R-MMU-69229	Ubiquitin-dependent degradation of Cyclin D1	48	15	4.1E-05
R-MMU-75815	Ubiquitin-dependent degradation of Cyclin D	48	15	4.1E-05
R-MMU-351202	Metabolism of polyamines	82	20	4.3E-05
R-MMU-69601	Ubiquitin Mediated Degradation of Phosphorylated Cdc25A	49	15	4.3E-05
R-MMU-69610	p53-Independent DNA Damage Response	49	15	4.3E-05
R-MMU-69613	p53-Independent G1/S DNA damage checkpoint	49	15	4.3E-05
R-MMU-5607761	Dectin-1 mediated noncanonical NF-kB signaling	56	16	4.7E-05

D Formation of fibrin clot (clotting cascade) genes significantly higher Mtb HN878 infection in Parp9-/-mice but not B6 mice

and taken			Z score of gene expression					
Gene ID	Name	Description	B6	PARP9 KO	B6	PARP9 KO		
			uninfected	uninfected	infected	infected		
ENSMUSG0000028001	Fga	fibrinogen alpha chain						
ENSMUSG0000033860	Fgg	fibrinogen gamma chain						
ENSMUSG0000033831	Fgb	fibrinogen beta chain						
ENSMUSG0000027249	F2	coagulation factor II		and the second second				
ENSMUSG0000022875	Kng1	kininogen 1						
ENSMUSG0000026715	Serpinc1	serine (or cysteine) peptidase inhibitor, clade C (antithrombin), r						
ENSMUSG0000021492	F12	coagulation factor XII (Hageman factor)						
ENSMUSG0000047953	Gp5	glycoprotein 5 (platelet)						
ENSMUSG0000024386	Proc	protein C						
ENSMUSG0000060459	Kng2	kininogen 2						
ENSMUSG0000031138	F9	coagulation factor IX						
ENSMUSG0000050675	Gp1ba	glycoprotein 1b, alpha polypeptide						
ENSMUSG0000031443	F7	coagulation factor VII				1999		
ENSMUSG0000029373	P14	platelet factor 4						
ENSMUSG0000022766	Serpind1	serine (or cysteine) peptidase inhibitor, clade D, member 1						
ENSMUSG00000109764	Kikb1	kallikrein B, plasma 1						
ENSMUSG0000031645	F11	coagulation factor XI						
					<-1.5 -0.75	0 0.75 >1.5 >2		
			Z score of e	expression (Log FI	PKM)			

Supplementary Figure 5. Fibrin clotting cascade genes are upregulated in *Mtb*-infected

Parp9^{-/-} mice.

B6 or *Parp9*-^{/-} mice were infected with *Mtb* HN878 (100 CFU) by the aerosol route and RNA isolated from mouse lung homogenates (30dpi) was subjected to bulk RNA sequencing. (A) Principal component analysis (PCA) plot of the mouse RNA-seq samples showing that most of the variance between samples (87%) comes from differences between uninfected vs. infected mice, but *Parp9*-^{/-} has distinct expression profiles from B6, especially after infection. (B) Venn diagram showing overlap of genes significantly higher in *Mtb* HN878-infected B6 and *Parp9*-^{/-} mice. (C) Significant Reactome pathway enrichment among the 1,104 genes considerably higher during *Mtb* HN878 infection in *Parp9*-^{/-} mice but not B6 mice and (D) heat map showing upregulation of clotting cascade genes during *Mtb* HN878 infection in *Parp9*-^{/-} mice but not B6 mice.

Supplementary Figure 6.



В

Complement cascade genes significantly higher during Mtb HN878-infection in Parp9-/- mice but not B6 mice

				Z score of	gane expression		
Gene (D	Rame	Description	80 uninfected	MARPS KO unimboled	M stated	PARPS KD Hecelei	
ENSAUSG0000021349 ENSAUSG0000021199 ENSAUSG0000023116	12 QA2 QA2	scepulation factor II carboxyoptitase K2 (plasma) carboxyoptitase K, polyoptita 2			-		
ENSMUSCO0000000011 ENSMUSCO0000013888	04	complement component II, alpha polypepilde complement factor H-related 2	1				Z score of expression (Log FIPEM)
ENSALISGO000019063 ENSALISGO000019063 ENSALISGO0000037942	010 010 010	complement tactor H-related K complement complement R, gamma polycieptide C-reactive protein, pertravio-related	. 10		100		
ENSMUSG000000010134 ENSMUSG0000000919	Celli Magli	CO18 antigen mannen-binding techt senne peptidawa 2				and so the	
ENSWU000000021148	Ciar I	conglement component 8		-			
ENGMUSG0000029656 ENGMUSG0000029616	08	conglienteit component B, bela jolyceptide conglienteit receptor 2			-		
	EXERCISIONNET HIM EXERCISIONNET HIM EXERCISIONNET HIM EXERCISIONNET HIM EXERCISIONNET HIM EXERCISIONNET HIM EXERCISIONNET HIM EXERCISIONNET HI EXERCISIONNET HI EXERCISIONNET HI EXERCISIONNET HIM EXERCISIONNET HIM EXERCISIONNET EXERCISIONNET HIM EXERCISIONNET HIM EXERCISIONNET	INIMUSQUIDDETHIP CAU INIMUSQUIDDETHIP CAU INIMUSQUIDDETHIP CAU INIMUSQUIDDETHIP CAU INIMUSQUIDDETHIP CAU INIMUSQUIDDETHIP CAU INIMUSQUIDDETHIP INIQUI INIMUSQUIDDETHIP INIQUI INIMUSQUIDDETHIP CAU INIMUSQUIDDETHIP CAU INIMUSQUIDDETHIP CAU INIMUSQUIDDETHIP CAU INIMUSQUIDDETHIP CAU INIMUSQUIDDETHIP CAU INIMUSQUIDDETHIP CAU INIMUSQUIDDETHIP CAU	NUMUSG00000017144 F2 cosputative factor il NUMUSG00000017144 CpAD antiocosputatiane K2 (staming) NUMUSG00000017141 CpAD antiocosputatiane K2 (staming) NUMUSG00000017141 CpAD complement marginerani 1, alpho polycepittle NUMUSG00000017141 CpAD complement tactor 1 + rolated 2 NUMUSG000000170544 CPAD complement tactor 1 + rolated 1 NUMUSG000000170544 CPAD complement tactor 1 + rolated 2 NUMUSG000000170544 CPAD complement tactor 1 + rolated 1 NUMUSG00000017054 CPAD complement tactor 1 + rolated 1 NUMUSG00000017054 CPAD complement tactor 1 + rolated 1 NUMUSG00000017054 CPAD complement computer K gamma polycepittle NUMUSG00000017054 CPAD complement computer K gamma polycepittle NUMUSG000000017055 CDID complement tactor 1 + rolated 1 NUMUSG00000001705 CDID complement tactor 1 + rolated 1 NUMUSG00000001705 CDID complement tactor 1 + rolated 1 NUMUSG00000001705 CDID complement tactorolated patron 1 N	INIMUSQU0000021146 F2 cosputation factor II INIXUUSQU0000021118 Carlocaysthiame Exit Jiaming conjenent tampament II, Alpha porpuptite INIXUUSQU000020111 Child complement tampament II, Alpha porpuptite INIXUUSQU000020111 Child complement tampament II, Alpha porpuptite INIXUUSQU0000201104 Child complement tampament II, Alpha porpuptite INIXUUSQU0000201104 Child complement tampament II, Alpha porpuptite INIXUUSQU0000201104 Child complement tampament II, Alpha porpuptite INIXUUSQU000001104 Child complement tampament II, Alpha porpuptite INIXUUSQU00001104 Child Child III annama holding tach - serve population 2 INIXUUSQU0000104116 Child III annama holding tach - serve population 2 complement onsparent 1 attach 1 INIXUUSQU0000104116 Child III annama holding tach - serve population 2 complement comparent 3 IIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIII	Gene ID Name Description No PARPS 00 antifactor EX084/5000000001044 72 cooptation factor II antifactor antifactor EX084/5000000001044 CpU antifactor antifactor antifactor EX084/5000000001044 CpU antifactor antifactor antifactor antifactor EX084/500000001044 CpU antifactor antifactor antifactor antifactor EX084/500000001044 CpU antifactor antifactor antifactor antifactor EX084/500000001044 CPU antifactor antifactor antifactor antifactor EX084/5000000010544 CPU antifactor antifactor antifactor antifactor EX084/500000001054 CPU antifactor antifactor antifactor antifactor EX084/500000001054 CPU antifactor antifactor antifactor antifactor EX084/500000001054 CPU antifactor antifactor antifactor antifactor EX084/5000000001054 <	Mildle/S00000001114 F2 cosputation factor II amilitation Mildle/S000000001114 Cpic/ cosputation factor II cosputation factor II Mildle/S000000001114 Cpic/ component company file for polyceptide Mildle/S00000000111 Cpic/ complement company file for polyceptide Mildle/S0000000110 Chill complement tack in Installad file file file Mildle/S0000000100 Chill complement tack in Installad file file file file Mildle/S00000010104 Chill complement tack in Installad file file<	Gene ID Name Description Md FAMPS KD anticase Md PAMPS KD anticase EMIANUSCONDUCTIVE INSTANDISCONDUCTI

				2 8100 101	Ave a symposite	the second se	
dans D	hatte	Description		PARTERO	- Harrison	Statistics.	
EN SACESCONDUCTION DATA DASARANDORODORE SOLS DASARANDORODORE SOLS	Apost Apost	plante teoripopeto: A1 F/P, anta 2 carrientati ita	-	1	Des PC MARKE	10.00	
ENDAUSCONTROLING FILTER	Ty The	Aufrie bin gebrie Lagtbase mitdebilden Aufreiter 12 Bandlynde Benadigeste	12 11 ^{ma}		-		
Exdat/sconsociated	Ang	epta-1xt5-porpresi			100	1.0.00	
ENDAUBOROOCERCE I	2	Entropper piging chain. Unit-law	1.1			-	
EN-SAUS-00000000141 EN-SAUS-000000001400	N Deris	attantic () fording protein unterceptedense 10	-	-			
Purskusteren en e	Applant A	species and the server is welfamily a propagate 11	-			-11 Tare	
ENERGINGROUPS TYPE ENERGINGROUPS TYPE	Politike Addate Economic	Inputo suchar factor 4, apha printeer 8, Nuclear Stephinghate substrate PADI, family 2 subfamily 6 pulpotetists 8					
Ex-Security concentration Ch-Security concentration EX-SEAL (Sponsore Concentration)	Appent	sponyoperation Autority Construction Strength Strength Strength State	-		al la c		
INSAUSCO00000H681	Page 1	produce prolongers required injustrative groups in the product of			100.00	1000	2 score of expression (Log (TPOI)
THERADOLOGOOD FLA ENGAUSODOOD TITS ENGRUSODOOD TITS	DAT Here	anoffene Jesaflooptee, atuduna 1 Biadenezyfranograme typingam	-		100	a des regions	5 pcose or excerning in the second se
The Data Laboration of	Repire to	munnegature 1			1.0 10		
ENDMUNCOCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCC	Sales Gales	Romagen task-dram grouth differentiation linker 18 substream PADI, family 2 autolemity 6 polycapitols 15					
IN SMUSSION OF STREET	High Block	Supermethylated in caread 1 adular carter feetly 27 fully part increased in 1 member 2			1000	and it is not the	
Ex-SALUSCODOCI T249 Ex-SALUSCODOCID23875	10 6001	unagulation factor 8 Konnegari 1				A DECISION OF	
EN:SMUISOR00000010064 EN:EMUISOR00000050440	BCBAR Het	actuale carrier territy 28, insertion 2 Entyphicing/hamploprovin actual disanglementer	10	and the second s	CARD BE	10.00	
ThisAculturenced files ENSALIPURSCORES FILE ENERGY CONSISTENT	Epuit I	ATP aconing-search, sub-tentry 8 (ADA/TAP), memory 11 elongation of which g chain hets acces (PEPP/REQ, SUBAEC) parties to cyclemet.peg/does infidder, clade A, member 34			-		
The DALING CONCEPTION	Lipitute	UCP plusammungmamahmaar 2 kemily, petyampiste 834			100		
ENIMATECONODUCED 711	begins?	same to reduce the other with the chart pressure			100	Concession in the local division of the loca	

Supplementary Figure 6. Genes belonging to the complement cascade and the serine peptidase family are upregulated in *Mtb* HN878-infected *Parp9^{-/-}* mice

B6 or *Parp9-/-* mice were infected with *Mtb* HN878 (100 CFU) by the aerosol route and RNA derived from lung homogenates of mice at 30dpi was subjected to bulk RNA sequencing. (A) heat map showing upregulation of complement cascade genes during *Mtb* HN878 infection in *Parp9^{-/-}* mice but not B6 mice. (B) heat map showing upregulation of serine-peptidase family members during *Mtb* HN878-infection in *Parp9^{-/-}* mice but not B6 mice. Significantly differentially expressed genes between B6 and *Parp9^{-/-} Mtb*-

infected lungs were identified using DESeq2 P value significance threshold of 0.05 (after FDR correction).

Supplementary Figure 7.



Supplementary Figure 7. Coexpression and correlation between Parp9 and members of the complement and coagulation pathways

Gene co-expression networks based on all RNA-seq data analyzed in the (A) DO mouse immune correlates and (B) human adolescent cohort study (ACS) (3)and the mouse DO immune correlates (1). Within each species' dataset, Pearson correlation values between pairs of two genes were calculated, quantifying the similarity of their expression (normalized gene expression data; Log FPKM) across all samples analyzed. (C) Correlation between *PARP9* gene expression and relative protein abundance in humans, using a previously-published protein microarray by using Pearson correlation values (4)

(Penn-Nicholson 2019).

References

- 1. Ahmed M, Thirunavukkarasu S, Rosa BA, Thomas KA, Das S, Rangel-Moreno J, et al. Immune correlates of tuberculosis disease and risk translate across species. *Science Translational Medicine*. 2020;12(528):eaay0233.
- 2. Scriba TJ, Penn-Nicholson A, Shankar S, Hraha T, Thompson EG, Sterling D, et al. Sequential inflammatory processes define human progression from M. tuberculosis infection to tuberculosis disease. *PLoS Pathog.* 2017;13(11):e1006687-e.
- Zak DE, Penn-Nicholson A, Scriba TJ, Thompson E, Suliman S, Amon LM, et al. A blood RNA signature for tuberculosis disease risk: a prospective cohort study. *The Lancet*. 2016;387(10035):2312-22.
- 4. Penn-Nicholson A, Hraha T, Thompson EG, Sterling D, Mbandi SK, Wall KM, et al. Discovery and validation of a prognostic proteomic signature for tuberculosis progression: A prospective cohort study. *PLOS Medicine*. 2019;16(4):e1002781.